Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer

BJU International

Volumn 110, Issue 11 C, 2012, Pages

  Laurberg, Jens R ^a   Brems Eskildsen, Anne S ^a   Nordentoft, Iver ^a   Fristrup, Niels ^a   Schepeler, Troels ^a   Ulhøi, Benedicte P ^b   Agerbæk, Mads ^a   Hartmann, Arndt ^b   Bertz, Simone ^b   Wittlinger, Michael ^c   Fietkau, Rainer ^c   Rödel, Claus ^d   Borre, Michael ^a   Jensen, Jørgen B ^a   Ørntoft, Torben ^a   Dyrskjøt, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Bladder cancer; Cystectomy; Marker; MRE11; Radiotherapy; TIP60

Indexed keywords

CARBOPLATIN; CISPLATIN; DEOXYRIBONUCLEOPROTEIN; FLUOROURACIL; GEMCITABINE; KI 67 ANTIGEN; MEIOTIC RECOMBINATION 11 PROTEIN; ONCOPROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TAT INTRERACTIVE PROTEIN 60; UNCLASSIFIED DRUG; DNA; DNA BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; KAT5 PROTEIN, HUMAN; MRE11A PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ATAXIA TELANGIECTASIA; BLADDER CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CORRELATION ANALYSIS; CYSTECTOMY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; BIOPSY; BIOSYNTHESIS; BLADDER TUMOR; CANCER INVASION; COMPARATIVE STUDY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE ACETYLTRANSFERASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

MLCS; MLOWN;

EID: 84873269524     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11564.x     Document Type: Article

References (28)

1. Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE . Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center . Int J Radiat Oncol Biol Phys 2008; 70: 456-63
2. Cobo M, Delgado R, Gil S et al . Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer . Clin Transl Oncol 2006; 8: 903-11
3. Efstathiou JA, Spiegel DY, Shipley WU et al . Long-term outcomes of selective bladder preservation by combinedmodality therapy for invasive bladder cancer: the MGH experience . Eur Urol 2012; 61: 705-11
4. Rodel C, Grabenbauer GG, Kuhn R et al . Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results . J Clin Oncol 2002; 20: 3061-71 (Pubitemid 34791095)
5. Stenzl A, Cowan NC, De Santis M et al . Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines . Eur Urol 2011; 59: 1009-18
6. James ND, Hussain SA, Hall E et al . Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer . N Engl J Med 2012; 366: 1477-88
7. Sun Y, Jiang X, Price BD . Tip60: connecting chromatin to DNA damage signaling . C ell Cycle 2010; 9: 930-6
8. Jiang H, Reinhardt HC, Bartkova J et al . The combined status of ATM and p53 link tumor development with therapeutic response . Genes Dev 2009; 23: 1895-909
9. Shariat SF, Tokunaga H, Zhou J et al . p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer . J Clin Oncol 2004; 22: 1014-24 (Pubitemid 41095033)
10. Matsushita K, Cha EK, Matsumoto K et al . Immunohistochemical biomarkers for bladder cancer prognosis . Int J Urol 2011; 18: 616-29
11. Jensen JB, Munksgaard PP, Sorensen CM et al . High expression of karyopherin-alpha2 defi nes poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy . Eur Urol 2011; 59: 841-8
12. R ö del C, Weiss C, Sauer R . Trimodality treatment and selective organ preservation for bladder cancer . J Clin Oncol 2006; 24: 5536-44 (Pubitemid 46631334)
13. Heebøll S, Borre M, Ottosen PD et al . SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation . Histol Histopathol 2008; 23: 1069-76
14. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J . HPV-associated p16-expression and response to hypoxic modifi cation of radiotherapy in head and neck cancer . Radiother Oncol 2010; 94: 30-5
15. Agerbaek M, Alsner J, Marcussen N, Lundbeck F, von der Maase H . Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer . Br J Cancer 2003; 89: 298-304 (Pubitemid 36976319)
16. Moonen L, Ong F, Gallee M et al . Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder . Int J Radiat Oncol Biol Phys 2001; 49: 1305-10 (Pubitemid 32294311)
17. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y . Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confi ned disease . Clin Cancer Res 2006; 12: 7369-73 (Pubitemid 46095410)
18. Choudhury A, Nelson LD, Teo MT et al . MRE11 expression is predictive of cause-specifi c survival following radical radiotherapy for muscle-invasive bladder cancer . Cancer Res 2010; 70: 7017-26
19. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E et al . ATM activation in normal human tissues and testicular cancer . Cell Cycle 2005; 4: 838-45 (Pubitemid 41353838)
20. Achour M, Jacq X, Ronde P et al . The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression . Oncogene 2008; 27: 2187-97 (Pubitemid 351483378)
21. Haller F, Agaimy A, Cameron S et al . Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis . Histopathology 2010; 56: 305-18
22. Vojtesek B, Bartek J, Midgley CA, Lane DP . An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53 . J Immunol Methods 1992; 151: 237-44
23. Key G, Becker MH, Baron B et al . New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope . Lab Invest 1993; 68: 629-36 (Pubitemid 23202791)
24. Stracker TH, Petrini JH . The MRE11 complex: starting from the ends . Nat Rev Mol Cell Biol 2011; 12: 90-103
25. Malats N, Bustos A, Nascimento CM et al . P53 as a prognostic marker for bladder cancer: a meta-analysis and review . Lancet Oncol 2005; 6: 678-86 (Pubitemid 41222758)
26. Grossman HB, Tangen CM, Cordon-Cardo C et al . Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study . Oncol Rep 2006; 16: 807-10
27. Stadler WM, Lerner SP, Groshen S et al . Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status . J Clin Oncol 2011; 29: 3443-9
28. Bussolati G, Leonardo E . Technical pitfalls potentially affecting diagnoses in immunohistochemistry . J Clin Pathol 2008; 61: 1184-92